M. Naveed Shaik

3.0k total citations · 1 hit paper
42 papers, 2.1k citations indexed

About

M. Naveed Shaik is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Pharmacy. According to data from OpenAlex, M. Naveed Shaik has authored 42 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 17 papers in Pathology and Forensic Medicine and 8 papers in Pharmacy. Recurrent topics in M. Naveed Shaik's work include Hedgehog Signaling Pathway Studies (28 papers), Tumors and Oncological Cases (17 papers) and Oral and gingival health research (8 papers). M. Naveed Shaik is often cited by papers focused on Hedgehog Signaling Pathway Studies (28 papers), Tumors and Oncological Cases (17 papers) and Oral and gingival health research (8 papers). M. Naveed Shaik collaborates with scholars based in United States, Italy and Germany. M. Naveed Shaik's co-authors include Sophia Randolph, Keith D. Wilner, Peter J. O’Dwyer, Gary K. Schwartz, Jörge E. Cortes, Patricia LoRusso, Rachel Courtney, Geoffrey Chan, Ashleigh O’Connell and Mirjana Zeremski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

M. Naveed Shaik

41 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Jörge E. Cortes, Florian H. Heidel et al. Leukemia profile →

Peers

Countries citing papers authored by M. Naveed Shaik

Since Specialization

Citations

This map shows the geographic impact of M. Naveed Shaik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Naveed Shaik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Naveed Shaik more than expected).

Fields of papers citing papers by M. Naveed Shaik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Naveed Shaik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Naveed Shaik. The network helps show where M. Naveed Shaik may publish in the future.

Co-authorship network of co-authors of M. Naveed Shaik

This figure shows the co-authorship network connecting the top 25 collaborators of M. Naveed Shaik. A scholar is included among the top collaborators of M. Naveed Shaik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Naveed Shaik. M. Naveed Shaik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring the Anthelmintic and Antidiabetic Effects of Rosarin in Preclinical Studies Using Zebrafish and Earthworm Models (Pheretima posthuma) 2025 ·Current Diabetes Reviews ·(unknown), (unknown), (unknown), M. Naveed Shaik, Prashant Tiwari	0
2	First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors 2025 ·ESMO Open ·Aung Naing, Meredith McKean, Lee S. Rosen, (unknown), M. Naveed Shaik, (unknown), (unknown), Katharina Kern, (unknown), Sharmistha Pal	2
3	Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Nirav N. Shah, Martin Lechmann, Hardik Mody, Marc W. Retter, Min Zhu, Tommy Li, Jun Wang, M. Naveed Shaik, (unknown), Meric Ovacik, Fei Hua, Vibha Jawa, Christophe Boetsch, Yanguang Cao, John M. Burke, (unknown), Kapil Gadkar, Vijay Upreti, Alison Betts	2
4	Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial 2023 ·Leukemia ·Mikkael A. Sekeres, Pau Montesinos, Jan Novák, Jianxiang Wang, Deepa Jeyakumar, Benjamin Tomlinson, Jiřı́ Mayer, Erin Jou, Tadeusz Robak, David Taussig, Hervé Dombret, Akil Merchant, M. Naveed Shaik, Thomas O’Brien, Whijae Roh, Xueli Liu, (unknown), (unknown), Geoffrey Chan, Jörge E. Cortes	15
5	Physiologically Based Pharmacokinetic Modeling of the Drug–Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study 2023 ·The Journal of Clinical Pharmacology ·Ernesto Callegari, Susanna Tse, Angela C. Doran, Theunis C. Goosen, M. Naveed Shaik	2
6	Lenacapavir: a first-in-class HIV-1 capsid inhibitor 2021 ·Current Opinion in HIV and AIDS ·Hadas Dvory‐Sobol, M. Naveed Shaik, Christian Callebaut, Martin S. Rhee	89
7	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure 2020 ·Cancer Chemotherapy and Pharmacology ·(unknown), M. Naveed Shaik, Geoffrey Chan, Jörge E. Cortes, Ana Ruiz-Garcı́a	7
8	Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials 2019 ·Future Oncology ·Jörge E. Cortes, Hervé Dombret, Akil Merchant, Tetsuzo Tauchi, (unknown), Barbara Sleight, Xiaoxi Zhang, Eric Leip, M. Naveed Shaik, Timothy Bell, Geoffrey Chan, Mikkael A. Sekeres	38
9	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS 2018 ·Clinical Cancer Research ·Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey E. Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	86
10	Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study 2018 ·Cancer Chemotherapy and Pharmacology ·M. Naveed Shaik, Brian Hee, Hua Wei, Robert R. LaBadie	17
11	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome breakdown → 2018 ·Leukemia ·Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, P. Desjardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser	354
12	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results 2018 ·American Journal of Hematology ·Jörge E. Cortes, Benjamin D. Smith, Eunice S. Wang, Akil Merchant, Vivian G. Oehler, Martha Arellano, Daniel J. DeAngelo, Daniel A. Pollyea, Mikkael A. Sekeres, Tadeusz Robak, Weidong Wendy, Mirjana Zeremski, M. Naveed Shaik, Alexander Laird, Ashleigh O’Connell, Geoffrey Chan, Mark A. Schroeder	94
13	Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers 2017 ·Cancer Chemotherapy and Pharmacology ·Nagdeep Giri, Lisa H. Lam, Robert R. LaBadie, Joseph F. Krzyzaniak, (unknown), Brian Hee, Yali Liang, M. Naveed Shaik	12
14	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study 2015 ·The Lancet Haematology ·Giovanni Martinelli, Vivian G. Oehler, Cristina Papayannidis, Rachel Courtney, M. Naveed Shaik, Xiaoxi Zhang, Ashleigh O’Connell, Karen R. McLachlan, Xianxian Zheng, Jerald P. Radich, Michele Baccarani, Hagop M. Kantarjian, Wendy J. Levin, Jörge E. Cortes, Catriona Jamieson	97
15	A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, Anthony B. El-Khoueiry	61
16	A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 2014 ·Clinical Cancer Research ·Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary, Antonio Jimeno, Arvind Dasari, Bo Huang, M. Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M. Reynolds, Patricia A. English, Karen R. McLachlan, Kenneth A. Kern, Patricia LoRusso	175
17	Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors 2013 ·OncoImmunology ·Robert H. Vonderheide, Jennifer M. Burg, Rosemarie Mick, (unknown), Dongguang Li, M. Naveed Shaik, Anthony W. Tolcher, Omid Hamid	155
18	Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer 2011 ·Clinical Cancer Research ·Keith T. Flaherty, Patricia LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, Gary K. Schwartz	295
19	A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·Wells A. Messersmith, P. LoRusso, (unknown), Arvind Dasari, (unknown), M. Naveed Shaik, Rachel Courtney, Sophia Randolph, Geoffrey I. Shapiro	4
20	Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies 2011 ·Blood ·Catriona Jamieson, Jörge E. Cortes, Vivian G. Oehler, Michele Baccarani, Hagop M. Kantarjian, Cristina Papayannidis, (unknown), Xiaoxi Zhang, M. Naveed Shaik, Rachel Courtney, Wendy J. Levin, Giovanni Martinelli	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact